These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21094366)

  • 1. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).
    Gerdts E; Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber C; Ray S; Skjærpe T; Wachtell K; Willenheimer R
    Am J Cardiol; 2010 Dec; 106(11):1634-9. PubMed ID: 21094366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
    Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Skjaerpe T; Wachtell K; Willenheimer R;
    N Engl J Med; 2008 Sep; 359(13):1343-56. PubMed ID: 18765433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial.
    Holme I; Boman K; Brudi P; Egstrup K; Gohlke-Baerwolf C; Kesäniemi YA; Malbecq W; Rossebø AB; Wachtell K; Willenheimer R; Pedersen TR
    Am J Cardiol; 2010 Jun; 105(12):1802-8. PubMed ID: 20538134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.
    Rossebø AB; Pedersen TR; Allen C; Boman K; Chambers J; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi VA; Malbecq W; Nienaber C; Ray S; Skjaerpe T; Wachtell K; Willenheimer R
    Am J Cardiol; 2007 Apr; 99(7):970-3. PubMed ID: 17398194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy.
    Hamilton-Craig I; Kostner K; Colquhoun D; Woodhouse S
    Heart Lung Circ; 2009 Oct; 18(5):343-6. PubMed ID: 19586799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction.
    Jander N; Minners J; Holme I; Gerdts E; Boman K; Brudi P; Chambers JB; Egstrup K; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Rossebø A; Pedersen TR; Skjærpe T; Willenheimer R; Wachtell K; Neumann FJ; Gohlke-Bärwolf C
    Circulation; 2011 Mar; 123(8):887-95. PubMed ID: 21321152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (the SEAS trial).
    Farmer JA
    Curr Atheroscler Rep; 2009 Mar; 11(2):82-3. PubMed ID: 19228479
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events.
    Rieck ÅE; Cramariuc D; Boman K; Gohlke-Bärwolf C; Staal EM; Lønnebakken MT; Rossebø AB; Gerdts E
    Hypertension; 2012 Jul; 60(1):90-7. PubMed ID: 22647889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
    Greve AM; Boman K; Gohlke-Baerwolf C; Kesäniemi YA; Nienaber C; Ray S; Egstrup K; Rossebø AB; Devereux RB; Køber L; Willenheimer R; Wachtell K
    Circulation; 2012 Jan; 125(2):346-53. PubMed ID: 22147903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mild-to-moderate aortic stenosis not improved by lipid-lowering therapy: SEAS study.
    Cardiovasc J Afr; 2008; 19(5):280-2. PubMed ID: 18997993
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.
    Green A; Ramey DR; Emneus M; Iachina M; Stavem K; Bolin K; McNally R; Busch-Sørensen M; Willenheimer R; Egstrup K; Kesäniemi YA; Ray S; Basta N; Kent C; Pedersen TR
    Am J Cardiol; 2014 Nov; 114(10):1518-22. PubMed ID: 25267716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy.
    Cramariuc D; Cioffi G; Rieck AE; Devereux RB; Staal EM; Ray S; Wachtell K; Gerdts E
    JACC Cardiovasc Imaging; 2009 Apr; 2(4):390-9. PubMed ID: 19580719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study).
    Greve AM; Bang CN; Boman K; Egstrup K; Forman JL; Kesäniemi YA; Ray S; Pedersen TR; Best P; Rajamannan NM; Wachtell K
    Am J Cardiol; 2018 Mar; 121(6):739-745. PubMed ID: 29361285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis.
    Greve AM; Bang CN; Boman K; Egstrup K; Kesäniemi YA; Ray S; Pedersen TR; Wachtell K
    Am J Cardiol; 2019 Dec; 124(11):1736-1740. PubMed ID: 31586530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezetimibe plus simvastatin cardiovascular outcomes study program.
    Padial LR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):17-25. PubMed ID: 18095904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of energy loss index in asymptomatic aortic stenosis.
    Bahlmann E; Gerdts E; Cramariuc D; Gohlke-Baerwolf C; Nienaber CA; Wachtell K; Seifert R; Chambers JB; Kuck KH; Ray S
    Circulation; 2013 Mar; 127(10):1149-56. PubMed ID: 23357717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
    Greve AM; Gerdts E; Boman K; Gohlke-Baerwolf C; Rossebø AB; Nienaber CA; Ray S; Egstrup K; Pedersen TR; Køber L; Willenheimer R; Wachtell K
    Int J Cardiol; 2013 Jun; 166(1):72-6. PubMed ID: 21996417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive lipid-lowering therapy for patients with aortic stenosis.
    Pedersen TR
    Am J Cardiol; 2008 Dec; 102(11):1571-6. PubMed ID: 19026317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic Stenosis [SEAS] substudy).
    Lund BP; Gohlke-Bärwolf C; Cramariuc D; Rossebø AB; Rieck AE; Gerdts E
    Am J Cardiol; 2010 May; 105(10):1456-60. PubMed ID: 20451694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.